BPC-157: What the Research Actually Shows

BPC-157 is a lab-made peptide that has sped up the healing of tendons, muscle, bone and gut in dozens of animal studies, mostly in rats. In people, the published evidence is three small studies with no control groups and 30 participants in total, and no country has approved BPC-157 as a medicine.

That gap is the whole story. Forums call it the “Wolverine peptide,” and clinics sell injections for sore knees and torn tendons. Meanwhile, the FDA’s own reviewers say there is not enough human safety data to judge it, even as an FDA advisory panel voted in July 2026 to let pharmacies compound it.

This guide sets out what BPC-157 is, what the animal studies measured, every human study we could find, the known and unknown risks, and where the law stands in late 2026. It is not a how-to. The only doses mentioned are study protocols, reported as study details.

What Is BPC-157?

BPC stands for “body protection compound,” a protein that researchers isolated from human gastric juice. BPC-157 is a synthetic 15-amino-acid piece of it, with the sequence GEPPPGKPADDAGLV, according to a 2003 rat tendon study. It is a pentadecapeptide, which simply means a peptide 15 amino acids long.

You can’t get it from food, and your body doesn’t make BPC-157 itself. Every vial, capsule or nasal spray sold under the name contains a peptide made in a lab.

Where the Research Comes From

Predrag Sikirić’s group at the University of Zagreb first described BPC-157 in 1993. Pharmaceutical company Pliva later tested it under the code name PL 14736. The group describes the peptide as stable in human gastric juice, which is the basis for many claims that it works when swallowed. We found no independent study confirming that stability.

The research base is narrow. In our own PubMed search on October 28, 2026, about three in four of the 236 records on BPC-157 listed Sikirić as an author. A 2019 review noted that “only a handful of research groups” had studied it in depth. One group producing most of the evidence doesn’t make that evidence wrong, but it does mean few results have been independently repeated.

Want the quick reference version? BPC-157 also has an entry in our Compound Index, with its status and the key studies on one page.

BPC-157 Research in Animals: What Was Measured

Almost everything people say about BPC-157 benefits comes from animal and cell studies. Most used rats, and most gave the peptide by injection into the abdomen (intraperitoneal) at doses measured in micrograms or nanograms per kilogram of body weight.

Tendons and Ligaments

In the 2003 study, rats with a cut Achilles tendon got BPC-157 at 10 µg, 10 ng or 10 pg per kilogram once a day. Their tendons were stronger under load, scored better on a walking-function index and looked more organized under the microscope than those of untreated rats.

One of the few teams outside Zagreb, at Chang Gung University in Taiwan, looked at tendon cells. In their 2011 study, tendon cells exposed to BPC-157 grew out of tissue samples faster, survived chemical stress better and migrated more. BPC-157 did not directly make them divide faster.

A 2014 follow-up from the same team found more growth hormone receptors on rat tendon cells, which made them respond more strongly to growth hormone. This was a dish experiment only. It is not evidence that BPC-157 raises growth hormone in people, though forum posts often present it that way.

Muscle and Bone

In a 2008 study, rats with crushed calf muscles got BPC-157 by injection or as a cream, daily for 14 days. They had less bruising and swelling and better function than untreated rats.

In rabbits with a gap cut into a leg bone, BPC-157 led to healing comparable to a bone graft. The doses used were 10 µg/kg applied locally, or 10 µg or 10 ng/kg injected into muscle.

The Gut

The gut is where BPC-157 research started, because of its gastric origins. Rat studies report healing of fistulas between the colon and bladder and of colitis and surgical joins in the colon. Some of these gave the peptide in drinking water rather than by injection, and both routes were reported to work in rats.

Blood Vessels: The Proposed Mechanism

The leading explanation for these effects is new blood vessel growth (angiogenesis). In a 2017 study from the Taiwan team, BPC-157 increased VEGFR2, a receptor that drives blood vessel growth, and sped up blood flow recovery in rats with a blocked leg artery. Other studies point to effects on nitric oxide.

Keep that mechanism in mind. Faster blood vessel growth helps a healing tendon, but it is also the reason some doctors raise cancer questions, covered in the safety section below.

Why Rat Results Don’t Transfer Easily

Rat results are a starting point, not proof. Three things make the jump to people harder than it looks:

• The doses are tiny and the route is unusual. Most rats got µg/kg or ng/kg doses injected into the abdomen, which is not how people use BPC-157.
• It doesn’t last long. In rats and dogs, BPC-157 had a half-life of under 30 minutes and broke down into small fragments and amino acids.
• Most results come from one lab. Independent groups, such as the Taiwan team, have confirmed parts of the picture, mostly in cell studies.

BPC-157 in Humans: Every Published Study

Here is the entire published human evidence base as of October 2026. All three studies come from the same first author, Edwin Lee, and his Florida clinics, and all appeared in the same journal.

Without a placebo group, there is no way to separate a drug effect from natural recovery or expectation. That matters for pain, which often improves on its own and responds strongly to placebo.

The Unpublished Colitis Trial

Pliva did run a controlled trial in the early 2000s, but it was never published in full. According to the FDA’s 2026 review, 53 people with ulcerative colitis got an 80 mg BPC-157 enema or placebo once a day for two weeks.

The BPC-157 group’s disease scores dropped further, but the FDA’s estimate of the difference between groups had a confidence interval that crossed zero. In plain terms, the trial didn’t show a clear benefit. BPC-157 also wasn’t detected in the blood after the enemas.

A separate oral BPC-157 trial registered in 2015 never posted results.

What Reviews Conclude in 2025 and 2026

Every recent review lands in the same place:

• A 2025 systematic review of BPC-157 in sports medicine screened 544 records and included 36 studies: 35 preclinical and one clinical. It found no clinical safety data.
• A 2026 systematic review of human evidence found three studies with 30 participants, all of poor quality, and rated the certainty “very low.”
• A review published October 27, 2026 in the Journal of the American Academy of Orthopaedic Surgeons concluded that “routine clinical use cannot be currently recommended.”

Trials Now Underway

Better data may be coming. A randomized, placebo-controlled trial of BPC-157 injections for hamstring strains began recruiting in China in February 2026, aiming for 120 participants, with completion estimated in 2028. A University of Arkansas study of BPC-157 after rotator cuff surgery is listed as not yet recruiting.

Is BPC-157 Safe? What’s Known and What Isn’t

The honest answer is that nobody knows. That isn’t the same as saying it’s dangerous. It means the studies needed to judge safety in people haven’t been done.

What the FDA Found

The FDA reviewed BPC-157 in depth for its July 2026 advisory meeting. Its briefing document concluded there is “insufficient clinical safety information to characterize the safety profile” of BPC-157. Among its other findings:

• No carcinogenicity studies have been done, so long-term cancer risk is untested.
• No human pharmacokinetic data exist for oral, under-the-skin, nasal or transdermal use, the routes most people use.
• Animal toxicity studies found no serious toxicity in mice, rats, rabbits and dogs, but 28-day studies flagged changes in blood clotting time and some liver-related markers.
• Three adverse event reports turned up in the FDA’s database, all with injected products: an injection-site reaction, shortness of breath leading to an emergency room visit, and skin and gum darkening that came back when the person used the product again.

The Cancer Question

Because BPC-157 promotes blood vessel growth in animals, some doctors worry it could feed tumors that need a blood supply to grow. A 2026 review on unregulated peptides lists “pathological angiogenesis” and carcinogenesis among the risks. This is a theoretical concern, not an observed one. No human data link BPC-157 to cancer, and no data rule it out either.

What’s Actually in the Vial

Most BPC-157 is sold as a “research chemical,” not for human use, so nobody checks it the way pharmacies check medicines. The FDA describes both forms it reviewed as “not well-characterized” for identity, purity and contaminants. It has also sent warning letters over BPC-157, including one in 2019 to a compounding pharmacy that made BPC-157 acetate, a substance the FDA said was not eligible for compounding.

A certificate of analysis helps, but only if you know how to read one. Our guide on how to read a peptide COA explains what a COA proves and what it doesn’t. For the wider picture, see our overview of peptide side effects.

Oral vs Injected BPC-157

Online sellers offer capsules, nasal sprays and injectable powders, and the claims for each differ. Here’s what the research actually covers:

• In rats: both injected and oral (in drinking water) BPC-157 were reported to work in gut and fistula studies.
• In people: the published studies used injections into the knee, the bladder wall or a vein, plus enemas in the unpublished colitis trial. The one oral human trial never reported results.
• Absorption: there are no human data showing how much oral, under-the-skin or nasal BPC-157 reaches the bloodstream.

“BPC-157 arginate,” sold as a more stable oral form, has no peer-reviewed studies at all in PubMed. The FDA evaluated only the free base and acetate forms. Treat “arginate” as a marketing term until someone publishes data.

Is BPC-157 Legal? The 2026 Picture

The legal status of BPC-157 shifted several times in 2026, and it is still moving. Our broader guide to whether peptides are legal covers the general rules.

Not an Approved Drug

No country has approved a medicine containing BPC-157, according to the FDA. In the US, products marketed for human use are unapproved drugs, which is why “research use only” labels are so common.

FDA and Compounding

Compounding pharmacies can only make drugs from approved ingredients or substances on special lists. The FDA previously placed BPC-157 in Category 2, its list of bulk substances that may present “significant safety risks.” As of April 2026, the FDA lists it among substances whose nominations were withdrawn, with its safety concerns still noted. That did not make it legal to compound.

On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding BPC-157 to the list of substances pharmacies may compound, for ulcerative colitis. FDA staff had recommended against it, citing a lack of evidence that it works. The vote is advice, not a decision.

Then, on October 15, 2026, the Associated Press reported that HHS had sent an “interim access policy” for peptides to the White House for review. Two unnamed sources said it would let pharmacies temporarily compound popular peptides, including BPC-157. As of October 31, 2026, the policy was still under White House review, and no final FDA action had been announced.

Athletes and the Military

BPC-157 is banned at all times under WADA’s S0 category for non-approved substances, where the Prohibited List names it as an example. It is also on the US Department of Defense’s prohibited dietary supplement ingredients list.

How BPC-157 Compares to TB-500

BPC-157 is often stacked with TB-500, a synthetic fragment of thymosin beta-4 sold for the same injury claims. TB-500 has its own thin evidence base and is also banned by WADA. Our guide to TB-500 covers that research, and our article on TB-500 vs BPC-157 compares the two.

Combining two compounds with little human safety data doesn’t make either one better understood. No published study has tested the combination in people.

If you want new peptide research explained when it’s published, including results from the BPC-157 trials now underway, the Morning Dose newsletter covers it every Monday.